Stuttgart - Delayed Quote EUR

Astellas Pharma Inc (YPH.SG)

Compare
9.25
-0.08
(-0.84%)
At close: January 10 at 8:11:18 AM GMT+1
Currency in JPY All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
1,603,672,000.00
1,603,672,000.00
1,518,619,000.00
1,296,163,000.00
1,249,528,000.00
Cost of Revenue
292,485,000.00
292,485,000.00
288,353,000.00
253,009,000.00
246,063,000.00
Gross Profit
1,311,187,000.00
1,311,187,000.00
1,230,266,000.00
1,043,154,000.00
1,003,465,000.00
Operating Expense
1,292,240,000.00
1,292,240,000.00
1,098,709,000.00
912,191,000.00
867,892,000.00
Operating Income
18,947,000.00
18,947,000.00
131,557,000.00
130,963,000.00
135,573,000.00
Net Non Operating Interest Income Expense
-550,000.00
-550,000.00
-669,000.00
1,200,000.00
9,273,000.00
Pretax Income
24,969,000.00
24,969,000.00
132,361,000.00
156,886,000.00
145,324,000.00
Tax Provision
7,924,000.00
7,924,000.00
33,647,000.00
32,800,000.00
24,734,000.00
Net Income Common Stockholders
17,045,000.00
17,045,000.00
98,714,000.00
124,086,000.00
120,589,000.00
Diluted NI Available to Com Stockholders
17,045,000.00
17,045,000.00
98,714,000.00
124,086,000.00
120,589,000.00
Basic EPS
2.87
9.51
54.24
67.08
64.93
Diluted EPS
2.65
9.47
54.09
67.05
64.90
Basic Average Shares
1,797,429.75
1,793,276.62
1,820,019.00
1,849,713.00
1,857,125.00
Diluted Average Shares
1,806,631.25
1,799,660.00
1,825,061.00
1,850,602.00
1,858,193.00
Total Operating Income as Reported
25,518,000.00
25,518,000.00
133,029,000.00
155,686,000.00
136,051,000.00
Total Expenses
1,584,725,000.00
1,584,725,000.00
1,387,062,000.00
1,165,200,000.00
1,113,955,000.00
Net Income from Continuing & Discontinued Operation
17,045,000.00
17,045,000.00
98,714,000.00
124,086,000.00
120,589,000.00
Normalized Income
10,399,436.50
10,399,436.50
98,555,891.74
104,916,906.00
120,589,000.00
Interest Income
11,455,000.00
11,455,000.00
8,110,000.00
6,149,000.00
11,608,000.00
Interest Expense
12,005,000.00
12,005,000.00
8,779,000.00
4,949,000.00
2,335,000.00
Net Interest Income
-550,000.00
-550,000.00
-669,000.00
1,200,000.00
9,273,000.00
EBIT
36,974,000.00
36,974,000.00
141,140,000.00
161,835,000.00
147,659,000.00
EBITDA
194,814,000.00
194,814,000.00
246,878,000.00
241,519,000.00
220,311,000.00
Reconciled Cost of Revenue
292,485,000.00
292,485,000.00
288,353,000.00
253,009,000.00
246,063,000.00
Reconciled Depreciation
157,840,000.00
157,840,000.00
105,738,000.00
79,684,000.00
72,652,000.00
Net Income from Continuing Operation Net Minority Interest
17,045,000.00
17,045,000.00
98,714,000.00
124,086,000.00
120,589,000.00
Total Unusual Items Excluding Goodwill
9,735,000.00
9,735,000.00
212,000.00
24,234,000.00
--
Total Unusual Items
9,735,000.00
9,735,000.00
212,000.00
24,234,000.00
--
Normalized EBITDA
185,079,000.00
185,079,000.00
246,666,000.00
217,285,000.00
220,311,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
3,089,436.50
3,089,436.50
53,891.74
5,064,906.00
--
3/31/2021 - 12/28/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

KY4.DU Kyowa Kirin Co Ltd
13.80
0.00%
 
D4S.MU Daiichi Sankyo Co Ltd
25.79
-1.04%
 
D4S.DU Daiichi Sankyo Co Ltd
25.83
+0.66%
 
D4S.F Daiichi Sankyo Company, Limited
25.00
-1.38%
 
KYKOF Kyowa Kirin Co., Ltd.
15.00
+5.26%
 
ZEGA.F AstraZeneca PLC
65.00
+1.56%
 
GSK GSK plc
33.09
-1.96%
 
JNJ Johnson & Johnson
142.06
-0.15%
 
ABBV AbbVie Inc.
175.17
-1.87%
 
NVO Novo Nordisk A/S
86.26
+0.72%